Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

Neuro-Oncology

Volumn 15, Issue 8, 2013, Pages 1079-1087

  Lu Emerson, Christine ^a   Snuderl, Matija ^a   Kirkpatrick, Nathaniel D ^a   Goveia, Jermaine ^a   Davidson, Christian ^a   Huang, Yuhui ^a   Riedemann, Lars ^a   Taylor, Jennie ^a   Ivy, Percy ^b   Duda, Dan G ^a   Ancukiewicz, Marek ^a   Plotkin, Scott R ^a   Chi, Andrew S ^a   Gerstner, Elizabeth R ^a   Eichler, April F ^a   Dietrich, Jorg ^a   Stemmer Rachamimov, Anat O ^a   Batchelor, Tracy T ^a   Jain, Rakesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

antiangiogenic therapy; glioblastoma; myeloid cells; relapse

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; AUTOPSY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; TUMOR ASSOCIATED LEUKOCYTE;

ANTIANGIOGENIC THERAPY; GLIOBLASTOMA; MYELOID CELLS; RELAPSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; AUTOPSY; BRAIN NEOPLASMS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84880667542     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not082     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase IIclinical trials. J Clin Oncol. 1999;17:2572-2578. (Pubitemid 29368260)
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
4. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followedbybevacizumab plus irinotecanattumor progressioninrecurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
5. Reardon DA, Turner S, Peters KB, et al. Areview of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011;9:414-427.
6. Chinot O. Phase III trial of bevacizumab added to standard radiotherapy andtemozolomide fornewlydiagnosedglioblastoma: matureprogression free survival and preliminary overallsurvival results. In AVAglio, Society for Neuro-Oncology 17th Annual Scientific Meeting and Education Day. Washington DC.: Neuro-Oncology, 2012.
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307.
8. di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapyin patients: lack of "rebound" revascularizationasmode of escape. Cancer Res. 2011;71:19-28.
9. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
10. Denardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov. 2011;1:54-67.
11. Bingle L, Brown NJ, Lewis CE. Therole of tumour-associated macrophages in tumour progression: implications for newanticancer therapies. J Pathol. 2002;196:254-265. (Pubitemid 34189413)
12. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulatingfactor1promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193:727-740.
13. Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216:15-24.
14. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999;5:1107-1113. (Pubitemid 29233226)
15. Rossi ML, Jones NR, Candy E, et al. The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol. 1989;78:189-193. (Pubitemid 19160923)
16. Galarneau H, Villeneuve J, Gowing G, et al. Increased Glioma Growth in Mice Depleted of Macrophages. Cancer Res. 2007;67:8874-8881. (Pubitemid 47437464)
17. Okada M, Saio M, Kito Y, et al. Tumor-associated macrophage/microglia infiltration in humangliomasis correlated with MCP-3, butnot MCP-1. Int J Oncol. 2009;34:1621-1627.
18. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25:911-920. (Pubitemid 47236916)
19. de Groot JF, Piao Y, Tran H, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011;17:4872-4881.
20. Hothorn T, Hornik K, vande Wiel MA, et al. A Lego System for Conditional Inference. The American Statistician. 2006;60:257-263. (Pubitemid 44257518)
21. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216.
22. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40. (Pubitemid 43108832)
23. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73:1200-1206.
24. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787.
25. Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol. 2012;2012:193436.
26. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11: 889-896.
27. Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell. 2011;19:1-2.
28. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612. (Pubitemid 43165918)
29. Oosterling SJ, van der Bij GJ, Meijer GA, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol. 2005;207:147-155. (Pubitemid 41404145)
30. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233-242.
31. Delay M, Jahangiri A, Carbonell WS, et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res. 2012;18:2930-2942.
32. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15:4589-4599.
33. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) Tcells regulate pulmonary metastasis of mammary carcinomasbyenhancing protumor properties of macrophages. Cancer Cell. 2009;16:91-102.
34. Hiratsuka S, Duda DG, Huang Y, et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proceedings of the National Academy of Sciences. 2011;108:302-307.
35. Yao Y, Kubota T, Sato K, et al. Macrophage Infiltration-associated Thymidine Phosphorylase Expression Correlates with Increased Microvessel Density and Poor Prognosis in Astrocytic Tumors. Clinical Cancer Research. 2001;7:4021-4026. (Pubitemid 34044622)
36. Engler JR, Robinson AE, Smirnov I, et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One. 2012;7:e43339.